Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0RU5 stock hub

LON/0RU5 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0RU5is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

16.8M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0RU5

In the news

Latest news · LON/0RU5

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROE-121.8

P25 -54.2P50 2.1P75 13.7

ROIC-74.5

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0RU5 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

157

Groups with data

Currency

NOK

Showing 157 of 157 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Norway
Country code	UK
Employees	44
Employees Change	2%
Employees Change Percent	5.88
Enterprise value	NOK 2.9M
Exchange	London Stock Exchange
Financial currency	NOK
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	NO0013711713
Last refreshed	2026-05-10
Market cap	NOK 16.8M
Price	NOK 46.2
Price currency	NOK
Rev Per Employee	47,018.93x
Sector	Healthcare
Sic	2836
Symbol	lon/0RU5
Website	https://www.oncoinvent.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-68.22%
EV Earnings	-0.25x
EV/FCF	-0.3x
EV/Sales	1.3x
FCF yield	-57.18%
P/B ratio	1.55x
P/S ratio	8.1x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	NOK 2.1M
Gross Profit Growth	40.37%
Gross Profit Growth Q	100.46%
Gross Profit Growth3 Y	71.34%
Gross Profit Growth5 Y	69.54%
Net Income	NOK -11.4M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-552.46%
Profit Per Employee	NOK -259,761
ROA	-52.64
Roa5y	-44.11
ROCE	-107.7
ROE	-121.8
Roe5y	-97.98
ROIC	-74.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth	246.4x
Revenue Growth Q	100.46x
Revenue Growth Quarters	1x
Revenue Growth Years	2x
Revenue Growth3 Y	71.34x
Revenue Growth5 Y	35.01x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	NOK 0.15
Assets	NOK 15.1M
Cash	NOK 13.1M
Current Assets	NOK 14.9M
Current Liabilities	NOK 4.6M
Debt	NOK 261,654
Debt Equity	NOK 0.02
Debt FCF	NOK -0.03
Equity	NOK 10.8M
Liabilities	NOK 4.3M
Long Term Assets	NOK 187,301
Long Term Liabilities	NOK -294,757
Net Cash	NOK 12.8M
Net Cash By Market Cap	NOK 76.57
Net Cash Growth	37.9%
Net Debt Equity	NOK -1.19
Tangible Book Value	NOK 10.8M
Tangible Book Value Per Share	NOK 0.02

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.23
Net Working Capital	NOK -3.3M
Quick ratio	3.2
Working Capital	NOK 9.5M
Working Capital Turnover	NOK 0.02

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-395.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
50-day SMA	45.96
All Time High	132
All Time High Change	-65%
All Time High Date	2025-11-04
All Time Low	40.2
All Time Low Change	14.93%
All Time Low Date	2026-03-03
ATR	1.2
Ch YTD	-5.71
High	46.2
High52	132
High52 Date	2025-11-04
High52ch	-65%
Low	45.2
Low52	40.2
Low52 Date	2026-03-03
Low52ch	14.93%
Ma50ch	0.52%
RSI	44.86
RSI Monthly	0
RSI Weekly	19.94
Sharpe ratio	-1.21x
Sortino ratio	-1.55
Total Return	-395.91%
Tr YTD	-5.71
Tr1m	-0.67%
Tr1w	-3.75%
Tr3m	7.35%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	NOK -11.7M
Operating margin	-564.1

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,998,256%
Net Borrowing	-200,955.1
Shares Insiders	1.27%
Shares Qo Q	25,157.21%
Shares Yo Y	395.91%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	NOK -9.9M
Average Volume	434x
Bv Per Share	0.02
CAPEX	NOK -8,771
Ch1m	-0.67
Ch1w	-3.75
Ch3m	7.35
Ch6m	-62.44
Change	0.43%
Change From Open	2.21
Close	46
Days Gap	-1.74
Depreciation Amortization	679,806.5
Dollar Volume	23,238.6
Earnings Date	2026-04-22
EBIT	NOK -11.7M
EBITDA	NOK -11M
EPS	NOK -0.09
F Score	2
FCF	NOK -9.6M
FCF EV Yield	-330.39x
Financing CF	8,786,405
Fiscal Year End	December
Founded	2,007
Investing CF	248,092
Is Primary Listing	0
Last Earnings Date	2026-04-22
Last Report Date	2025-12-31
Last Split Date	2026-01-19
Last Split Type	Reverse
Ma20	48.28
Ma20ch	-4.31%
Net CF	3,241,189
Next Earnings Date	2026-08-27
Open	45.2
Position In Range	100
Ppne	1,241,015.2
Price Date	2026-05-08
Ptbv Ratio	1.55
Relative Volume	1.16x
Revenue	2,068,833x
SBC By Revenue	13.8x
Share Based Comp	285,461
Tr6m	-41.39%
Volume	503
Z Score	-0.78

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0RU5 pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns LON/0RU5?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

+1.3%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+395.9%

Negative means the company is buying back shares.

Technical

LON/0RU5 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.9

Neutral momentum band

Price vs 200-day MA

n/a

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-1.21

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0RU5

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0RU5 stock rating?

lon/0RU5 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0RU5 analysis?

The full report lives at /stocks/lon/0RU5/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0RU5?

The latest report frames lon/0RU5 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0RU5 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.